Compare ENRD & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENRD | OLMA |
|---|---|---|
| Founded | N/A | 2006 |
| Country | Sweden | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 858.4M | 949.3M |
| IPO Year | 2025 | 2020 |
| Metric | ENRD | OLMA |
|---|---|---|
| Price | $4.90 | $10.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $44.89 |
| AVG Volume (30 Days) | 152.8K | ★ 953.1K |
| Earning Date | N/A | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 15.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.63 | $5.99 |
| 52 Week High | $10.49 | $36.26 |
| Indicator | ENRD | OLMA |
|---|---|---|
| Relative Strength Index (RSI) | 38.67 | 44.14 |
| Support Level | $4.69 | $9.70 |
| Resistance Level | $5.50 | $11.36 |
| Average True Range (ATR) | 0.68 | 0.43 |
| MACD | -0.08 | -0.02 |
| Stochastic Oscillator | 3.66 | 36.43 |
Einride AB is a technology company that develops and operates digital, electric, and autonomous freight solutions. Its platform includes planning and optimization tools, autonomous technologies, electric heavy-duty vehicle fleets, and charging infrastructure. It serves customers across North America, Europe, and the Middle East. The company's solutions support customers in transitioning logistics operations to electric and autonomous systems. Its business model includes Freight-Capacity-as-a-Service (FCaaS) and Software-as-a-Service (SaaS) offerings delivered through an AI-based platform that manages aspects of electric and autonomous operations.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.